MTOR and neoplasm: Furthermore, a novel dual PI3K/mTOR inhibitor, VDC-597, showed dose-dependent inhibition of both Akt1 and 4eBP1, reduction of proliferation, migration and VEGF production, and promotion of tumor cell apoptosis in three canine HSA cell lines (Pyuen et al., 2018).